Enclomiphene
Trans-isomer of clomiphene citrate, acting as a selective estrogen receptor modulator (SERM) at the hypothalamus. Blocks estrogen negative feedback on GnRH neurons, increasing pulsatile LH and FSH release from the anterior pituitary. Unlike zuclomiphene (the cis-isomer), enclomiphene has no significant estrogenic agonist activity, resulting in cleaner testosterone elevation without the visual or mood side effects of racemic clomiphene.
Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.
- total-testosterone
- free-testosterone
- lh
- fsh
- estradiol
- shbg
- liver-disease
- undiagnosed-vaginal-bleeding
- pituitary-tumor
- primary-hypogonadism
- PMID:24717915Enclomiphene citrate stimulates testosterone production while preventing oligospermia — J Urol, 2014
- PMID:27105355Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline — J Clin Endocrinol Metab, 2018
- PMID:26109534Nasal testosterone gel restores serum testosterone levels while maintaining sperm counts — J Sex Med, 2015
Enclomiphene solves the central problem of clomiphene therapy. Racemic clomiphene is a 50/50 mix of two molecules with opposing effects. Zuclomiphene is an estrogen agonist with a 30-day half-life that accumulates and causes visual disturbances, emotional blunting, and paradoxical estrogen activity. Enclomiphene is the pure antagonist with a 10-hour half-life. Clean in, clean out. The FDA never approved it despite multiple Phase III trials because of regulatory complications, not efficacy failures. Tier 2 reflects that regulatory limbo. The pharmacology is Tier 1 quality. The availability is not.
This is not medical advice
Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.
See Enclomiphene in a protocol matched to you